Amgen vs Gilead Sciences

Amgen (AMGN), health care, and Gilead Sciences (GILD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Amgen is worth $248.1B on the stock market and Gilead Sciences $210.7B: Amgen is valued at 18% more. Amgen's operating margin in its latest fiscal year was 24.7% and Gilead Sciences's 34.0%. Over the past year Amgen's share price has moved +34.4% and Gilead Sciences's +31.8%.

Key facts

Amgen market value
$248.1B
Gilead Sciences market value
$210.7B
Amgen P/E
26.6
Amgen revenue
$36.8BFY to 2025-12-31
Gilead Sciences revenue
$29.4BFY to 2025-12-31
Superinvestors holding both
5

Market values as of .

Amgen vs Gilead Sciences: every measure side by side
Measure Amgen Gilead Sciences
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$248.1Bhigher$210.7Blower
Revenue$36.8Bhigher$29.4Blower
Earnings$7.7Blower$8.5Bhigher
Employees31,500higher17,000lower
Total assets$90.6Bhigher$59Blower
Valuation
P/E26.6—
P/S6.8lower7.2higher
P/B17.3higher16.2lower
Dividend yield2.15%higher1.94%lower
Profitability
Operating margin24.7%lower34.0%higher
Balance sheet
Net assets$8.7Blower$22.7Bhigher
Total liabilities$81.9Bhigher$36.4Blower
Total debt$54.6Bhigher$24.9Blower
Cash on hand$9.1Bhigher$7.6Blower
Price change
Today-0.80%lower+1.39%higher
1 year+34.4%higher+31.8%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Amgen / Gilead Sciences). Who owns AMGN · Who owns GILD

Further comparisons

Learn

Questions and answers

Which is bigger, Amgen or Gilead Sciences?

By market value, Amgen is the larger: $248.1B against $210.7B for Gilead Sciences. By revenue in its latest fiscal year, Amgen is the larger: $36.8B against $29.4B for Gilead Sciences.

Which has the higher operating margin?

Gilead Sciences: 34.0%, against 24.7% for Amgen. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Amgen: 2.15%, against 1.94% for Gilead Sciences. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Amgen: $54.6B, against $24.9B for Gilead Sciences. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Amgen and Gilead Sciences?

In their latest 13F filings, Josef Lakonishok, David Shaw (founder), Fred DiSanto, Ken Griffin and Dodge & Cox team hold both.

Cite this page

Funkfolio, “Amgen vs Gilead Sciences”, data as of 17 November 2026. https://funkfolio.com/compare/amgn-vs-gild

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.